TITLE

Biovail shares depressed on Wellbutrin generic filing

PUB. DATE
January 2005
SOURCE
PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p10
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports that Biovail Corp.'s shares have hit a one-year low after it confirmed that Anchen Pharmaceuticals company had submitted an abbreviated new drug application to the U.S. Food and Drug Administration to market a generic version of antidepressant medication Wellbutrin XL. Formulations of Wellbutrin XL; Statement of CEO Douglas Squires regarding the company's intellectual property rights of Wellbutrin XL; Plan of Biovail to continue to develop a new and improved formulation of Wellbutrin XL.
ACCESSION #
17642289

 

Related Articles

  • Ivax next in line to market generic Celexa.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p10 

    Reports that shares in generic drugs manufacturer Ivax Corp. have seen a slight increase after it announced the receipt of final approval for its Celexa-equivalent antidepressant application in the U.S. Approval of the drug application by the U.S. Food and Drug Administration; Availability of...

  • GlaxoSmithKline receives FDA approvable letter for Wellbutrin XL.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p10 

    Reports on the approval of the antidepressant Wellbutrin XL tablets of GlaxoSmithKline PLC by the U.S. Food and Drug Administration. Increase in the treatment options for adults with depression; License agreement between the firm and Biovail Corp.; Efforts of the company to work with the agency...

  • Biovail files NDA for novel dosage form of anti-depressant.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12 

    Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.

  • Regulatory Update.  // PharmaWatch: CNS;Feb2005, Vol. 4 Issue 2, p15 

    The article presents updates related to pharmaceutical industry in the U.S. Biovail Corp. received an approval letter from the Food and Drug Administration for its orally disintegrating tablet version of tramadol hydrochloride as treatment for moderate to moderately severe pain. SCOLR Pharma...

  • CNS News Round-Up.  // PharmaWatch: CNS;Jun2009, Vol. 8 Issue 6, p2 

    The article offers world news briefs related to the pharmaceutical industry. The U.S. marketing rights to GlaxoSmithKline's (GSK) Wellbutrin XL tablets have been acquired by Biovail Corp. for £510 million. The orally disintegrating version of Lamictal from GSK has been approved by the U.S....

  • Drug approvals will give Forest Labs booster shot. Fung, Amanda // Crain's New York Business;11/5/2007, Vol. 23 Issue 45, p4 

    The article focuses on the pharmaceutical company Forest Laboratories Inc. The U.S. Food and Drug Administration is expected to approve the company's new hypertension drug, Nebivolol, in very near future. The company's shares have slipped 28% in 2007 over investors' anxiety about patent...

  • Acorda Gets Refusal to File Letter for Fampridine-SR.  // Bioworld Week;4/6/2009, Vol. 17 Issue 14, p4 

    The article reports on the decline of the shares of Acorda Therapeutics Inc. by 20% on the news that the Food & Drug Administration (FDA) had refused to accept its new drug application for Fampridine-SR in the U.S. The drug is designed specifically to improve walking ability in multiple...

  • Drug Watch.  // Formulary;Feb2004, Vol. 39 Issue 2, p124 

    Presents various antidepressant agents in late-stage development and approval by the U.S. Food and Drug Administration as of February 2004. New drugs; Latest indications/combinations/formulations; Information resouces on drug development.

  • CNS News Round-Up.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p2 

    The article offers world news briefs related to the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has approved Aricept 23 milligram once-daily tablets for the treatment of Alzheimer's disease. The marketing authorization application for OraVerse, a local anesthesia...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics